Nach Genre filtern
Oncology Today with Dr Neil Love

- 702 - Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 3: An Interview with Dr Matthew Lunning on the Utility of Tafasitamab
Featuring an interview with Dr Matthew Lunning, including the following topics:
Tafasitamab for follicular lymphoma (0:00)frontMIND Phase III trial of tafasitamab/lenalidomide/R-CHOP for diffuse large B-cell lymphoma (7:51)CME information and select publications
Mon, 16 Nov 2026 - 15min - 701 - Follicular Lymphoma — Where We Are, Where We're Headed in the Use of Bispecific Antibodies
Featuring perspectives from Prof Chan Chea and Dr Matthew Matasar, including the following topics:
Introduction (0:00)Prologue: Saturday Night Fever (1:35)Baby Boomers' Guide to Mechanisms of Action (3:07)Second-Line Treatment (12:36)Complications Associated with Bispecific Antibodies (23:41)Case Presentations (25:52)New Bispecific T-Cell Engagers — Surovatamig (26:24)Other Novel Agents (50:05)CME information and select publications
Fri, 13 Nov 2026 - 57min - 700 - Relapsed/Refractory Multiple Myeloma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Featuring perspectives from Dr Sagar Lonial and Dr Paul G Richardson, including the following topics:
Multiple Myeloma (0:00)Introduction: ESMO 2026; Recent FDA Approvals (1:53)Chimeric Antigen Receptor T-Cell Therapy — Dr Lonial (2:46)Bispecific Antibodies — Dr Lonial (19:16)Antibody-Drug Conjugates — Dr Richardson (37:08)Up-Front Treatment; Cereblon E3 Ligase Modulators — Dr Richardson (50:10)CME information and select publications
Wed, 11 Nov 2026 - 1h 02min - 699 - Prostate Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Featuring perspectives from Dr Neeraj Agarwal and Dr Emmanuel S Antonarakis, including the following topics:
Introduction: ESMO 2026; Recent FDA Approvals (0:00)Selection of Endocrine Therapy — Dr Antonarakis (2:24)Utility of PARP Inhibitors — Dr Agarwal (22:59)AKT Inhibition for PTEN-Deficient Disease — Dr Antonarakis (35:42)Radiopharmaceuticals — Dr Agarwal (45:02)CME information and select publications
Tue, 10 Nov 2026 - 58min - 698 - Breast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Featuring perspectives from Dr Charles E Geyer Jr, Dr Maryam Lustberg, Dr Rita Nanda and Dr Seth Wander, including the following topics:
Breast Cancer Introduction: ESMO 2026; Recent FDA Approvals (0:00)ER-Positive Breast Cancer (5:01)HER2-Positive Breast Cancer (1:19:08)Triple-Negative Breast Cancer (1:48:54)CME information and select publications
Mon, 09 Nov 2026 - 2h 22min - 697 - Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 2: An Interview with Dr Matthew Lunning on Novel Combination Regimens
Featuring an interview with Dr Matthew Lunning, including the following topics:
Bispecific antibody/antibody-drug conjugate combinations (0:00)A man in his late 90s with mantle cell lymphoma — Ann LaCasce, MD, MMSc (8:07)CME information and select publications
Fri, 06 Nov 2026 - 17min - 696 - Diffuse Large B-Cell Lymphoma — A Grand Rounds Program
Featuring a presentation by Dr Matthew Matasar, including the following topics:
Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (0:00)Clinician Survey Results Regarding First-Line Treatment of DLBCL (11:41)Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL (16:01)Clinician Survey Results Regarding the Use of Monoclonal and Bispecific Antibodies for R/R DLBCL (28:47)Evidence-Based Incorporation of Antibody-Drug Conjugates (ADCs) into the Management of R/R DLBCL (34:34)Clinician Survey Results Regarding the Use of ADCs for R/R DLBCL (46:31)Discussion of Questions from the Community (50:20)CME information and select publications
Wed, 04 Nov 2026 - 1h 01min - 695 - Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 1: An Interview with Dr Matthew Lunning on CNS Prophylaxis
Featuring an interview with Dr Matthew Lunning, including the following topics:
A woman in her late 70s with non-GCB diffuse large B-cell lymphoma receives pola-R-CHP — Ann LaCasce, MD, MMSc (0:00)CNS prophylaxis in non-Hodgkin lymphoma (7:58)CME information and select publications
Mon, 02 Nov 2026 - 18min - 694 - Hormone Receptor-Positive Localized Breast Cancer — A Grand Rounds Activity
Featuring an interview with Dr Erica Mayer, including the following topics:
Risk Assessment and Genomic Assays for Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer (0:00)Investigator Survey Results on Risk Assessment and Genomic Assays (20:07)Adjuvant CDK4/6 Inhibitors for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer (24:30)Investigator Survey Results on Adjuvant CDK4/6 Inhibitors (30:42)Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (32:07)Investigator Survey Results on Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (37:44)Adjuvant Oral Selective Estrogen Receptor Degraders (SERDs) for HR-Positive, HER2-Negative Localized Breast Cancer (39:05)Investigator Survey Results on Adjuvant Oral SERDs (43:02)Discussion of Questions from the Community (45:00)CME information and select publications
Thu, 29 Oct 2026 - 1h 00min - 693 - Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 6
Featuring perspectives from Dr Lindsey Roeker, including the following topics:
Case: A man in his mid 60s with TP53-aberrant chronic lymphocytic leukemia (CLL) with extensive marrow infiltration receives first-line venetoclax/obinutuzumab and experiences an excellent response (0:00)Case: A man in his late 70s with small lymphocytic lymphoma (SLL) and cardiovascular comorbidities requiring verapamil and anticoagulation receives acalabrutinib/venetoclax; Case: A man in his early 80s with SLL receives zanubrutinib/sonrotoclax as part of the CELESTIAL-TNCLL trial (14:46)Case: A man in his late 70s with progressive CLL worsening after a skiing injury receives acalabrutinib/venetoclax as part of the MAJIC trial (22:37)CME information and select publications
Wed, 28 Oct 2026 - 32min - 692 - Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 5
Featuring perspectives from Dr Lindsey Roeker, including the following topics:
Consensus Approach to optimizing front-line treatment (0:00)Emerging role of sonrotoclax (8:39)Bruton tyrosine kinase inhibitor monotherapy for older patients; discontinuation (14:48)Evolving role of minimal residual disease assessment (19:16)CME information and select publications
Wed, 28 Oct 2026 - 26min - 691 - Ovarian Cancer — Microlearning Activity 4: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer
Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:
Case: A woman in her early 70s with endometrioid carcinoma of the ovary and a large solitary brain metastasis after primary debulking surgery and adjuvant carboplatin/paclitaxel — Professor Jonathan A Ledermann (0:00)CME information and select publications
Tue, 27 Oct 2026 - 07min - 690 - Ovarian Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer
Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:
Case: A woman in her late 60s with a germline BRCA2 mutation and heavily pretreated ovarian cancer receives weekly nab paclitaxel and relacorilant — Angeles Alvarez Secord, MD, MHSc (0:00)CME information and select publications
Mon, 26 Oct 2026 - 19min - 689 - Prostate Cancer — An Interview with Prof Karim Fizazi
Featuring an interview with Prof Karim Fizazi, including the following topics:
Perspectives on the PROTEUS Phase III trial evaluating the addition of apalutamide to standard therapy for high-risk localized prostate cancer (0:00)Mechanism of action of opevesostat and potential role in castration-resistant prostate cancer with androgen receptor mutations (15:37)Perspectives on alpha- and beta-emitting radiopharmaceuticals in the treatment of prostate cancer (22:47)Novel antibody-drug conjugates and proteolysis-targeting chimeras (30:43)Treatment approaches for metastatic hormone-sensitive prostate cancer — de novo symptomatic presentation versus PSMA-only metastatic recurrence after local therapy (34:51)Role of intermittent therapy in the treatment of prostate cancer (38:48)Treatment intensification approaches in prostate cancer (41:38)Case: A man in his late 60s with de novo PSMA PET-positive metastatic castration-sensitive prostate cancer (45:25)CME information and select publications
Fri, 23 Oct 2026 - 1h 01min - 688 - Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 4
Featuring perspectives from Prof Susana Banerjee, including the following topics:
Case: A woman in her mid 50s with multiregimen-recurrent low-grade serous ovarian cancer and a KRAS G12V mutation who receives avutometinib/defactinib with response, asymptomatic creatine phosphokinase elevation and mild facial rash — Dr Stover (0:00)Case: A woman in her early 30s with recurrent metastatic low-grade serous ovarian cancer, originally offered hospice due to poor condition, who receives avutometinib/defactinib with an excellent response — Dr Hussein (7:58)Case: A woman in her late 30s with multiregimen-recurrent folate receptor alpha-positive low-grade serous ovarian cancer (HER2 IHC 2+) who receives mirvetuximab soravtansine — Dr Cobb (18:21)CME information and select publications
Fri, 23 Oct 2026 - 28min - 687 - Low-Grade Serous Ovarian Cancer — 5-Minute Journal Club: Microlearning Activity 3
Featuring perspectives from Prof Susana Banerjee, including the following topics:
Overview of the biology and treatment of low-grade serous ovarian cancer (0:00)Mechanism of action of avutometinib/defactinib (10:16)RAMP 201 Trial: Avutometinib/defactinib in recurrent low-grade serous ovarian cancer (14:32)Ongoing clinical trials in low-grade serous ovarian cancer (27:57)CME information and select publications
Thu, 22 Oct 2026 - 32min - 686 - Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome
Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics:
Introduction and Overview of Bispecific Antibodies in the Clinic (0:00)Current and Future Role of Bispecific Antibodies in Non-Hodgkin Lymphoma — Dr Kamdar (15:58)Case: A man in his early 60s with diffuse large B-cell lymphoma (DLBCL) receives glofitamab (42:40)Case: A woman in her early 80s with follicular lymphoma (FL) receives mosunetuzumab (51:50)Mitigation and Management of Cytokine Release Syndrome (CRS) and Other Toxicities Associated with Bispecific Antibodies — Dr Crombie (1:00:39)Case: A woman in her early 80s with DLBCL receives glofitamab (1:18:50)Case: A woman in her early 70s with FL receives epcoritamab (1:26:38)Outpatient CRS Management in B-Cell Lymphomas — Ms Lynch (1:29:28)Case: A woman in her late 40s with FL receives epcoritamab (1:38:33)Case: A man in his early 70s with mantle cell lymphoma receives mosunetuzumab (1:46:26)CME information and select publications
Wed, 21 Oct 2026 - 1h 58min - 685 - Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies
Featuring a slide presentation from Dr Julia Rotow, including the following topics:
Rationale and potential clinical role of PD-1/PD-L1 x vascular endothelial growth factor (VEGF) bispecific antibodies in the treatment of non-small cell lung cancer (NSCLC) (0:00)Key findings from the Phase III HARMONi-6 study; ongoing Phase III HARMONi-3 study (5:12)Key findings from the Phase III HARMONi-2 study; ongoing Phase III HARMONi-7 study (9:59)Clinician insights about the potential role of ivonescimab in the front-line setting (12:02)Impetus for investigating ivonescimab in the relapsed/refractory (R/R) EGFR-mutant setting (14:01)Key findings from the Phase III HARMONi-A and HARMONi studies (16:07)Clinician insights about the potential role of ivonescimab in the treatment of R/R EGFR-mutant NSCLC; other novel PD-1/PD-L1 x VEGF bispecific antibodies under investigation (20:30)CME information and select publications
Sat, 17 Oct 2026 - 24min - 684 - Chronic Lymphocytic Leukemia — Microlearning Activity 2
Featuring perspectives from Dr Catherine C Coombs, including the following topics:
Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (0:00)Role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy for relapsed/refractory (R/R) CLL (10:42)Fixed-duration venetoclax in combination with epcoritamab for R/R CLL/SLL; management of Richter’s transformation (15:50)Novel Bruton tyrosine kinase degraders bexobrutideg (NX-5948) and tacabrutideg (BGB-16673) (22:51)CME information and select publications
Fri, 16 Oct 2026 - 27min - 683 - Chronic Lymphocytic Leukemia — Microlearning Activity 1
Featuring perspectives from Dr Catherine C Coombs, including the following topics:
Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10)Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05)Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22)CME information and select publications
Thu, 15 Oct 2026 - 24min - 682 - Ovarian Cancer — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer
Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:
Case: A woman in her mid 50s with BRCA1-mutated recurrent ovarian cancer receives mirvetuximab soravtansine — Ursula Matulonis, MD (0:00)CME information and select publications
Wed, 14 Oct 2026 - 12min - 681 - Ovarian Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer
Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:
Case: A woman in her early 50s with a germline BRCA1 mutation and ovarian cancer experiences disease recurrence after completing olaparib/bevacizumab maintenance therapy — Professor Jonathan A Ledermann (0:00)CME information and select publications
Tue, 13 Oct 2026 - 12min - 680 - Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting
Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics:
Introduction (0:00)New and Emerging Strategies with Bispecific Antibodies in Multiple Myeloma (MM) — Dr Raje (2:20)Utility of Antibody-Drug Conjugates for Relapsed/Refractory (R/R) MM — Dr Orlowski (23:33)Potential Role of Cereblon E3 Ligase Modulators and Other Promising Novel Agents and Strategies for R/R MM — Prof Dimopoulos (41:12)CME information and select publications
Mon, 12 Oct 2026 - 59min - 679 - Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 4 with Dr Sara M Tolaney
Featuring perspectives from Dr Sara M Tolaney, including the following topics:
Management of adverse events associated with TROP2-targeting antibody-drug conjugates (0:00)Managing brain metastases in triple-negative breast cancer (6:30)EGFR x HER3-directed bispecific antibodies for metastatic triple-negative breast cancer (mTNBC) (9:11)PD-1/PD-L1 x VEGF-directed bispecific antibodies for mTNBC (12:31)CME information and select publications
Sat, 10 Oct 2026 - 18min - 678 - Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney
Featuring perspectives from Dr Sara M Tolaney, including the following topics:
Mechanistic effects and potential resistance mechanisms of antibody-drug conjugates (0:00)First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients eligible for immunotherapy (7:13)First-line treatment of mTNBC in patients ineligible for immunotherapy (13:02)Antibody-drug conjugates for previously treated HER2-low metastatic breast cancer (19:15)CME information and select publications
Fri, 09 Oct 2026 - 25min - 677 - Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management
Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics:
Introduction (0:00)Minimal Residual Disease Assays in Community-Based Practice (1:24)New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12)Richter Transformation (30:43)Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Coombs (34:49)CME information and select publications
Thu, 08 Oct 2026 - 58min - 676 - HER2-Positive Gynecologic Cancers — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer
Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics:
Case: A woman in her mid 60s with Stage II uterine carcinosarcoma treated with surgery followed by paclitaxel/carboplatin, whole-pelvic radiation and vaginal cuff brachytherapy — Dr Angeles Alvarez Secord (0:00)Case: A woman in her mid 50s with ovarian cancer and a genomic instability score of 50, folate receptor alpha 90%, HER2 IHC 2+, and BRCA1/2 wild-type disease treated initially with surgery, carboplatin/paclitaxel and maintenance olaparib/bevacizumab — Dr Ursula Matulonis (8:46)CME information and select publications
Wed, 07 Oct 2026 - 13min - 675 - Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies
Featuring an interview with Dr L Elizabeth Budde, including the following topics:
Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study (17:30)Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and polatuzumab vedotin in the second-line setting (23:18)Case: A woman in her early 70s with R/R DLBCL receives glofitamab monotherapy in the third-line setting (32:52)Case: A man in his early 80s with R/R DLBCL experiences disease progression after lisocabtagene maraleucel therapy, which was bridged with epcoritamab and gemcitabine/oxaliplatin (37:35)CME information and select publications
Mon, 05 Oct 2026 - 47min - 674 - Lung Cancer — Proceedings from a Symposium Held in Conjunction with the American Oncology Network
Featuring perspectives from Dr Stephen V Liu and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:
Introduction (0:00)EGFR Mutations (2:23)HER2 Alterations (22:40)Available and Investigational Immunotherapies (32:14)Small Cell Lung Cancer (40:48)CME information and select publications
Sun, 04 Oct 2026 - 50min - 673 - Prostate Cancer with PTEN Deficiency — An Interview with Dr Neeraj Agarwal
Featuring an interview with Dr Neeraj Agarwal, including the following topics:
Impact of PTEN deficiency on PI3K/AKT/mTOR pathway; optimal approaches to testing (0:00)Approaches to monitoring for disease progression in patients who are PTEN deficient; prognostic significance and implications for testing (7:13)Potential usage of capivasertib as second-line therapy for metastatic androgen pathway modulation-naïve/-sensitive (APMN/S) prostate cancer (15:15)Managing treatment-related adverse events from capivasertib (20:08)Case: A man in his late 50s diagnosed with metastatic APMS prostate cancer and a PTEN deficiency who receives capivasertib (29:17)Case: A man in his late 70s diagnosed with high-volume metastatic APMN prostate cancer and a PTEN deficiency who experiences disease progression on androgen deprivation therapy and enzalutamide (40:39)CME information and select publications
Fri, 02 Oct 2026 - 52min - 672 - HER2-Positive Gynecologic Cancers — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer
Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics:
Case: A woman in her mid 60s with metastatic serous endometrial carcinoma that is HER2 IHC 3+ who received first-line carboplatin/paclitaxel/trastuzumab and second-line trastuzumab deruxtecan — Ursula Matulonis, MD (0:00)Commentary: Role of HER2-directed therapy in the maintenance setting for patients with HER2-positive disease — Professor Jonathan A Ledermann (12:29)CME information and select publications
Thu, 01 Oct 2026 - 23min - 671 - Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Held in Conjunction with the American Oncology Network
Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:
Introduction (0:00)First-Line Treatment (1:33)Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36)CME information and select publications
Thu, 01 Oct 2026 - 50min - 670 - Ovarian and Endometrial Cancer — Proceedings from a Symposium Held in Conjunction with the American Oncology Network
Featuring perspectives from Dr Shannon N Westin and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:
Introduction (0:00)Ovarian Cancer (2:22)Endometrial Cancer (37:48)CME information and select publications
Thu, 01 Oct 2026 - 51min - 669 - For Oncology Nurses: Non-Small Cell Lung Cancer with a ROS1 Fusion — An Interview with Dr Alexander E Drilon
Featuring an interview with Dr Alexander E Drilon, including the following topics:
Overview of targetable biomarkers in lung cancer (0:00)Biomarker testing for genomic alterations in lung cancer (5:24)Overview of ROS1 alterations in lung cancer (13:44)Efficacy data with ROS1 inhibitors for lung cancer (17:02)Safety data with ROS1 inhibitors for lung cancer (21:15)Case: A woman in her early 50s with a history of non-small cell lung cancer (NSCLC) undergoes biomarker testing to reveal a ROS1 fusion (28:56)Case: A man in his late teens diagnosed with de novo advanced NSCLC with a ROS1 alteration achieves a dramatic response to therapy (46:16)Case: A woman in her early 60s with a history of ROS1-altered NSCLC receives several ROS1 inhibitors (50:52)NCPD information and select publications
Wed, 30 Sep 2026 - 58min - 668 - Glucocorticoid Receptor Antagonists for Ovarian Cancer — An Interview with Professor Nicoletta Colombo
Featuring an interview with Professor Nicoletta Colombo, including the following topics:
Mechanistic effects and rationale underlying the use of relacorilant/nab paclitaxel (0:00)Rationale underlying the study design of the Phase II BELLA trial and avenues for future exploration (8:31)Definition of platinum ineligibility; importance of platinum-containing chemotherapy for patients with ovarian cancer (14:02)Findings from a Phase II trial and the subsequent confirmatory Phase III ROSELLA study (20:25)Phase III ROSELLA study: Subgroup analyses, patient-reported outcomes, insights into overall survival data and common adverse events (29:43)Considerations for therapeutic selection and sequencing of novel therapies; ongoing and future investigations (38:46)CME information and select publications
Tue, 29 Sep 2026 - 48min - 667 - Gastroesophageal Cancers — Proceedings from a Symposium Held in Conjunction with the American Oncology Network
Featuring perspectives from Dr Samuel J Klempner and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:
Introduction (0:00)First-Line Treatment of Metastatic Gastroesophageal Cancer (1:48)Management of HER2-Positive Gastroesophageal Cancer (25:11)Neoadjuvant Therapy for Gastroesophageal Cancer (45:13)Note to listeners: Subsequent to the recording of this symposium, the FDA approved zanidatamab in combination with chemotherapy with and without tislelizumab for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma based on results from the Phase III HERIZON-GEA-01 trial.
CME information and select publications
Mon, 28 Sep 2026 - 50min - 666 - Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Conjunction with the American Oncology Network
Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:
Introduction (0:00)First-Line Therapy (2:48)Relapsed/Refractory Disease (39:30)CME information and select publications
Mon, 28 Sep 2026 - 54min - 665 - Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Reviewing Recent Datasets from the 2026 ASCO Annual Meeting and EHA2026 Congress
Featuring perspectives from Dr Brad S Kahl, Dr Jeff Sharman and Dr Tanya Siddiqi, including the following topics:
Introduction (0:00)Trials in Progress (1:12)Chronic Lymphocytic Leukemia (7:09)Diffuse Large B-Cell Lymphoma (32:35)Mantle Cell Lymphoma (58:25)Follicular Lymphoma (1:14:49)CME information and select publications
Fri, 25 Sep 2026 - 1h 28min - 664 - HER2-Positive Gynecologic Cancers — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer
Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topic:
Case: A woman in her late 50s with a BRCA1 germline mutation and platinum- and PARP inhibitor-resistant metastatic ovarian cancer with low folate receptor alpha level and HER2 IHC 1+ — Professor Jonathan A LedermannCME information and select publications
Thu, 24 Sep 2026 - 09min - 663 - Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov
Featuring an interview with Dr Douglas W Sborov, including the following topics:
DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00)Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26)Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36)Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48)Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00)Prevention and management of ophthalmic events related to treatment with belamaf (21:27)Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49)Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27)Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53)CME information and select publications
Wed, 23 Sep 2026 - 49min - 662 - Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 2 with Dr David W Cescon
Featuring perspectives from Dr David W Cescon, including the following topics:
Clinical treatment of BRCA-mutated metastatic triple-negative breast cancer (0:00)CNS activity of TROP2-directed antibody-drug conjugates (5:36)Autoimmune considerations with immunotherapy (10:09)Treatment of oligoprogressive advanced breast cancer (17:31)CME information and select publications
Tue, 22 Sep 2026 - 23min - 661 - Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon
Featuring perspectives from Dr David W Cescon, including the following topics:
First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients not eligible for immunotherapy (0:00)First-line treatment of mTNBC in patients eligible for immunotherapy (12:05)Adverse events (19:39)CME information and select publications
Mon, 21 Sep 2026 - 29min - 660 - Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Gottfried E Konecny and Dr Brian M Slomovitz, including the following topics:
Introduction (0:00)Preventing Ovarian Cancer (1:04)Endometrial Cancer (5:27)Ovarian Cancer (25:36)Cervical Cancer (54:04)CME information and select publications
Thu, 17 Sep 2026 - 58min - 659 - Metastatic Bladder Cancer — Rapid Case Review Issue 8
Featuring perspectives from Dr Alexandra Drakaki, including the following topics:
Case: A man in his late 70s with diabetes and metastatic bladder cancer achieves radiographic response with enfortumab vedotin (EV) and pembrolizumab but develops uncontrolled hyperglycemia (0:00)Case: A man in his early 70s with muscle-invasive bladder cancer receives adjuvant nivolumab and experiences metastatic progression after 9 cycles of therapy (6:23)Case: A woman in her early 70s with Lynch syndrome and metastatic upper tract bladder cancer receives EV/pembrolizumab and develops myasthenia gravis (13:59)Case: A woman in her late 40s with FGFR3 mutant metastatic bladder cancer receives erdafitinib and experiences rising serum phosphate levels (20:04)CME information and select publications
Wed, 16 Sep 2026 - 25min - 658 - Metastatic Bladder Cancer — Rapid Case Review Issue 7
Featuring perspectives from Dr Alexandra Drakaki, including the following topics:
Case: A man in his early 80s with bladder cancer and metastatic progression in the viscera and lymph nodes receives enfortumab vedotin (EV) with pembrolizumab — Part 1 (0:00)Case: A man in his early 80s with metastatic bladder cancer achieves a complete response with EV/pembrolizumab therapy but develops gastrointestinal toxicity — Part 2 (5:37)Case: A man in his early 50s with metastatic bladder cancer receives second-line EV monotherapy intermittently (15:09)Case: A woman in her mid 60s with bladder cancer and a history of rheumatoid arthritis develops oligometastatic progression in the lung and receives EV monotherapy (21:03)Case: A man in his mid 80s with HER2-positive (IHC 3+) metastatic bladder cancer receives trastuzumab deruxtecan and develops ground glass opacities in his lungs concerning for pneumonitis (30:43)CME information and select publications
Wed, 16 Sep 2026 - 36min - 657 - Breast Cancer — Reviewing Key Presentations from the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Aditya Bardia, Dr Kevin Kalinsky and Dr Joyce O'Shaughnessy, including the following topics:
Introduction (0:00)Hormone Receptor-Positive Breast Cancer — Dr Kalinsky (1:18)HER2-Positive Breast Cancer — Dr Bardia (42:46)Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:01:41)CME information and select publications
Tue, 15 Sep 2026 - 1h 29min - 656 - Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2
Featuring perspectives from Dr Rachel N Grisham, including the following topics:
Case: A woman in her early 40s with recurrent low-grade serous ovarian cancer (LGSOC) and prior treatment with a MEK inhibitor receives avutometinib/defactinib on the RAMP 301 trial (0:00)Case: A woman in her early 70s with recurrent KRAS-mutated LGSOC receives avutometinib/defactinib and develops muscle weakness (10:03)Case: A woman in her late 70s with KRAS-mutated recurrent LGSOC develops congestive heart failure on trametinib and then receives avutometinib/defactinib (16:15)Case: A woman in her mid 60s with recurrent BRAF V600E LGSOC has concerns about side effects and receives single-agent dabrafenib (19:49)CME information and select publications
Mon, 14 Sep 2026 - 26min - 655 - Low-Grade Serous Ovarian Cancer — 5-Minute Journal Club: Microlearning Activity 1
Featuring perspectives from Dr Rachel N Grisham, including the following topics:
Mechanism, clinical evidence and practical use of avutometinib with defactinib for recurrent low-grade serous ovarian cancer (LGSOC) (0:00)A Phase III trial of letrozole alone as front-line treatment for LGSOC (11:11)Current and future role of avutometinib with defactinib for LGSOC (19:23)A Phase II/III trial of trametinib for recurrent LGSOC: Biomarker analyses and clinical implications (21:37)CME information and select publications
Sun, 13 Sep 2026 - 28min - 654 - Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus
Featuring an interview with Prof Andreas Hochhaus, including the following topics:
Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00)Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09)Potential mechanisms of adverse events documented with TKIs (10:23)Recent survey of patients with CML regarding goals of therapy and clinical implications; considerations for discontinuation of therapy (16:23)Comparative tolerability of asciminib and other agents used to manage CML; promoting adherence to treatment plans for patients (27:14)Comparative efficacy of asciminib and other agents used to treat CML (40:01)Potential areas for improvement in community oncology practice patterns; family planning in the context of CML treatment (43:53)Practical care strategies for CML patients; future developments (52:32)CME information and select publications
Fri, 11 Sep 2026 - 59min - 653 - Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer
Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:
Case: A woman in her late 60s with recurrence of metastatic estrogen receptor-positive endometrial cancer enrolls in a trial of CDK4/6 inhibition with an aromatase inhibitor 1 year into maintenance dostarlimab after carboplatin/paclitaxel/dostarlimab and has no evidence of disease 3 years later (0:00)Adding a PARP inhibitor to immunotherapy and chemotherapy: The RUBY Part 2 and DUO-E trials (10:03)CME information and select publications
Fri, 11 Sep 2026 - 20min - 652 - Non-Small Cell Lung Cancer — Targeting KRAS G12C
Featuring perspectives from Prof Solange Peters and Dr Joshua K Sabari, including the following topics:
Introduction (0:00)Best Option for Your Patient (1:28)Biological Considerations (6:26)KRAS G12C Inhibitors (11:33)Second-Line Treatment (13:02)Current Clinical Trials in the First-Line Metastatic Setting (32:18)Current Clinical Trials in the Localized Setting (49:52)Current Clinical Trials with New Treatment Combinations and Agents (53:51)CME information and select publications
Thu, 10 Sep 2026 - 57min - 651 - Prostate Cancer — The Optimal Use of Hormonal Therapy
Featuring perspectives from Dr William K Oh and Dr Mary-Ellen Taplin, including the following topics:
Introduction: Another Perspective on the Treatment of Localized Prostate Cancer (0:00)Nonmetastatic Disease (10:32)Metastatic Androgen Pathway Modulation-Naïve and Androgen Pathway Modulation-Sensitive Disease (41:50)CME information and select publications
Tue, 08 Sep 2026 - 59min - 650 - Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 4
Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:
Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune hemolytic anemia receives acalabrutinib/venetoclax/obinutuzumab (0:00)Case: A man in his late 60s with bulky CLL diagnosed abroad receives zanubrutinib monotherapy (12:48)Case: A man in his late 40s with IGHV-mutated, del(13q) CLL with worsening symptoms and diffuse adenopathy after 1 year of observation receives venetoclax/obinutuzumab and attains a complete response (21:29)CME information and select publications
Mon, 07 Sep 2026 - 30min - 649 - Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3
Featuring perspectives from Prof John Seymour, including the following topics:
Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00)Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21)First-line treatment with sonrotoclax and zanubrutinib for CLL (13:10)CME information and select publications
Sun, 06 Sep 2026 - 22min - 648 - AKT Inhibition in Prostate Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:
Tolerability of capivasertib and management of associated side effects — Question from Neeraj Agarwal, MD, FASCO (0:00)Case: A man in his early 70s with Type 2 diabetes presents with metastatic hormone-sensitive prostate cancer with widespread bone metastases and PTEN deficiency on next-generation sequencing and receives relugolix/darolutamide — Rana R McKay, MD, FASCO (8:39)CME information and select publications
Sat, 05 Sep 2026 - 17min - 647 - ER-Positive, HER2-Positive Metastatic Breast Cancer — Patterns of Care Among Community Oncologists
Featuring perspectives from Dr Lisa A Carey and Dr Maha Hussain, including the following topics:
Introduction (0:00)HER2 History (1:32)Cases from the GMO Survey (7:06)Biology and Selection of First-Line Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer (mBC) — Dr Mahtani (19:56)Faculty Case Presentations (31:37)Patterns of Care Survey — Part 1 (38:26)Optimizing the Use of Up-Front Maintenance Therapy for HER2-Positive mBC — Dr Carey (44:53)Faculty Case Presentations (54:13)CME information and select publications
Thu, 03 Sep 2026 - 58min - 646 - Relapsed/Refractory Chronic Lymphocytic Leukemia — A Grand Rounds Program
Featuring perspectives from Dr William G Wierda, including the following topics:
Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00)Sequencing Road Map (12:39)Key Datasets — Pirtobrutinib (21:08)Investigator Survey (34:09)Chimeric Antigen Receptor T-Cell Therapy (45:08)Other Novel Therapy Approaches (49:58)EHA 2026 (54:45)CME information and select publications
Wed, 02 Sep 2026 - 58min - 645 - Lambert-Eaton Myasthenic Syndrome in Small Cell Lung Cancer — An Interview with Prof Ticiana Leal
Featuring an interview with Prof Ticiana Leal, including the following topics:
Pathophysiology and clinical signs and symptoms (0:00)Screening and/or diagnostic approaches (5:45)Potential impact of available therapies for small cell lung cancer (SCLC) on paraneoplastic syndromes (7:36)Key clinical trial data for amifampridine and practicalities of its administration (14:05)Building awareness among patients, caregivers and the oncology community (22:37)Role of pyridostigmine in managing Lambert-Eaton myasthenic syndrome (LEMS); potential integration of EMG (electromyography) into monitoring (25:35)Case: A man in his early 70s who receives a diagnosis of limited-stage SCLC (LS-SCLC) with LEMS and undergoes treatment (27:41)Case: A woman in her late 70s already diagnosed with LS-SCLC who is subsequently evaluated and treated for LEMS (37:55)Current research and potential developments in the treatment of SCLC (48:32)CME information and select publications
Tue, 01 Sep 2026 - 54min - 644 - For Oncology Nurses: Prostate Cancer — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Mr Michael Lai, Dr Scott T Tagawa, Ms Stacy E Walker and Dr Evan Y Yu, moderated by Dr Tagawa, including the following topics:
Introduction (0:00)Overview of Prostate Cancer (3:00)Hormonal Therapy for Nonmetastatic and Metastatic Hormone-Sensitive Prostate Cancer (HSPC) (6:12)Potential Role of Capivasertib in Metastatic HSPC (27:22)Current and Potential Future Role of PARP Inhibitors in Metastatic PC (46:39)Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic PC (1:09:14)CME information and select publications
Mon, 31 Aug 2026 - 1h 28min - 643 - Metastatic Triple-Negative Breast Cancer — Patterns of Care
Featuring perspectives from Prof Peter Schmid and Dr Melinda Telli, including the following topics:
Introduction: TROP2-Targeting Antibody-Drug Conjugates (ADCs) for Metastatic Triple-Negative Breast Cancer (0:00)First-Line Therapy (PD-L1 Negative) (6:53)First-Line Therapy (PD-L1 Positive) (23:40)Second-Line Therapy (Sequencing) (34:08)Adverse Events with TROP2-Targeting ADCs (43:43)CME information and select publications
Fri, 28 Aug 2026 - 1h 02min - 642 - Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:
Case: A patient with T4 disease, pelvic wall involvement and a positive pelvic node treated as metastatic disease with enfortumab vedotin and pembrolizumab attains a complete response on imaging after 6 cycles (0:00)Case: A man with muscle-invasive bladder cancer who receives neoadjuvant chemotherapy with durvalumab receives positive circulating tumor DNA results before cystectomy and negative results after surgery (7:41)CME information and select publications
Thu, 27 Aug 2026 - 15min - 641 - Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:
Case: A man in his early 80s with non-muscle-invasive bladder cancer (NMIBC) monitored by repeat TURBTs develops localized muscle-invasive bladder cancer and enrolls in a clinical trial of neoadjuvant enfortumab vedotin with pembrolizumab (0:00)Case: A man in his late 70s with newly diagnosed NMIBC with carcinoma in situ (CIS) receives BCG induction and experiences relapse of CIS during BCG maintenance (9:24)CME information and select publications
Wed, 26 Aug 2026 - 20min - 640 - Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets & the Advances
Featuring perspectives from Dr Matthew Matasar and Dr Sonali M Smith, including the following topics:
Introduction: Lymphoma Survivorship (0:00)Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Dr Matasar (6:49)Novel Treatment Approaches for Follicular Lymphoma and Mantle Cell Lymphoma — Dr Smith (32:14)CME information and select publications
Tue, 25 Aug 2026 - 1h 00min - 639 - For Oncology Nurses: Pancreatic Cancer — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Ms Caroline Kuhlman, Dr Eileen M O'Reilly, Dr Philip A Philip and Ms Amanda K Wagner, moderated by Dr O'Reilly, including the following topics:
Introduction (0:00)Clinical Presentation and Prognosis of Pancreatic Adenocarcinoma (PAD) (3:29)Recent Advances in Up-Front Treatment for Metastatic PAD (15:47)Selection and Sequencing of Therapy for Relapsed/Refractory Metastatic PAD (39:58)Novel Strategies Targeting RAS Mutations in Advanced PAD (48:20)Utility of Tumor Treating Fields in PAD Management (1:13:58)CME information and select publications
Mon, 24 Aug 2026 - 1h 28min - 638 - HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway
Featuring perspectives from Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics:
Introduction: San Antonio Memories (0:00)PI3K/AKT/PTEN Alterations and Therapies (7:18)Capivasertib (20:22)Gedatolisib (34:08)Inavolisib (47:07)New Agents and Ongoing Trials (52:34)CME information and select publications
Sun, 23 Aug 2026 - 58min - 637 - AKT Inhibition in Prostate Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:
Treatment approach for AKT-mutated prostate cancer — Question from Neeraj Agarwal, MD, FASCO (0:00)Case: A man in his late 60s with de novo metastatic hormone-sensitive prostate cancer with widespread skeletal metastases and PTEN loss on next-generation sequencing receives relugolix/darolutamide with chemotherapy and experiences PSA decline that plateaus at approximately 1 ng/mL — Rana R McKay, MD, FASCO (10:29)CME information and select publications
Sat, 22 Aug 2026 - 18min - 636 - AKT Inhibition in Prostate Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:
Role of PTEN deficiency in tumorigenesis of prostate cancer and optimal approach to PTEN assessment — Question from Neeraj Agarwal, MD, FASCO (0:00)Case: A man in his late 60s with a history of nonmetastatic hormone-sensitive prostate cancer (HSPC) that progressed to metastatic HSPC with PTEN loss by next-generation sequencing of primary archival tissue from 2017 receives abiraterone for 2 years — Rana R McKay, MD, FASCO (8:26)CME information and select publications
Fri, 21 Aug 2026 - 16min - 635 - Gastroesophageal Cancers — Year in Review Series on Relevant New Datasets and Advances
Featuring perspectives from Dr David H Ilson and Dr Kohei Shitara, including the following topics:
Introduction (00:00)Biomarker Evaluation in Localized and Metastatic Disease (1:49)Role of Immune Checkpoint Inhibitors in the Management of Gastroesophageal Cancers — Dr Ilson (7:37)Other Available Therapeutic Approaches — Dr Shitara (33:22)CME information and select publications
Wed, 19 Aug 2026 - 59min - 634 - Genitourinary Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Rahul Aggarwal, Dr Matthew D Galsky and Dr Tian Zhang, including the following topics:
Introduction: Welcome GU Oncology Fellows! (0:00)Prostate Cancer — Dr Aggarwal (12:48)Urothelial Bladder Cancer — Dr Galsky (45:01)Renal Cell Carcinoma — Dr Zhang (1:10:52)CME information and select publications
Wed, 19 Aug 2026 - 1h 30min - 633 - Metastatic Bladder Cancer — Rapid Case Review Issue 6
Featuring perspectives from Prof Yohann Loriot, including the following topics:
Case: A man in his early 80s with metastatic urothelial bladder cancer (mUBC) receives enfortumab vedotin (EV)/pembrolizumab but experiences immune-related adverse events requiring steroids and then develops neuropathy due to EV — Nazli Dizman, MD (0:00)Case: A man in his early 70s with diabetes who received adjuvant nivolumab for FGFR3-mutant metastatic urothelial cancer receives first-line EV monotherapy and experiences hyperglycemia and cancer progression, then receives erdafitinib and experiences elevated phosphase, Grade 2 diarrhea and stomatitis and eventual disease progression — Jacqueline T Brown, MD (7:00)Case: A man in his late 80s with mUBC receives first-line EV/pembrolizumab and develops pneumonitis — Fern Anari, MD (17:40)CME information and select publications
Tue, 18 Aug 2026 - 25min - 632 - For Oncology Nurses: Oral Selective Estrogen Receptor Degraders in Breast Cancer — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics:
Introduction (0:00)Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37)Practical Considerations with Oral SERDs (15:42)Potential Role of Combination Approaches with Oral SERDs (26:31)Gastrointestinal Adverse Events Documented with Oral SERDs (38:17)Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:51)Other Class-Effect Toxicities Associated with Oral SERDs (1:00:53)Emerging Utility of Adjuvant Oral SERDs (1:10:16)Unique Toxicities Associated with 1 or More Oral SERDs (1:19:17)CME information and select publications
Tue, 18 Aug 2026 - 1h 24min - 631 - Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances
Featuring perspectives from Dr Amrita Krishnan and Dr Robert Z Orlowski, including the following topics:
Introduction (00:00)Up-Front Progression-Free Survival for Standard-Risk Disease — 2006, 2016 (1:47)Current and Emerging Therapeutic Approaches — Dr Orlowski (10:34)Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Krishnan (27:15)ASCO and EHA 2026 (46:37)CME information and select publications
Mon, 17 Aug 2026 - 57min - 630 - Metastatic Bladder Cancer — Rapid Case Review Issue 5
Featuring perspectives from Prof Yohann Loriot, including the following topics:
Case: A man in his early 80s with Parkinson disease and a history of renal transplant presents with metastatic urothelial bladder cancer (UBC) and receives first-line enfortumab vedotin (EV) with a good response but develops neuropathy and skin toxicity — Jacqueline T Brown, MD (0:00)Case: A man in his early 90s with excellent PS and locally advanced UBC receives EV and pembrolizumab as palliative treatment, develops neuropathy, discontinues the EV and continues pembrolizumab with no toxicity — Catherine Fahey, MD, PhD (12:01)Case: A woman in her late 50s with metastatic UBC receives EV with pembrolizumab on a clinical trial and experiences a response but develops diarrhea and pruritus — Fern Anari, MD (21:43)CME information and select publications
Mon, 17 Aug 2026 - 28min - 629 - Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:
Case: A woman in her late 60s with T3N0 upper tract urothelial carcinoma that was resected has no evidence of disease on imaging, receives negative circulating tumor DNA results and elects observation instead of adjuvant treatment (0:00)Case: A man in his late 70s with PD-L1-negative high-grade muscle-invasive bladder cancer who is ineligible for cisplatin because of poor renal function undergoes cystectomy (10:12)CME information and select publications
Sat, 15 Aug 2026 - 20min - 628 - Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:
Case: A healthy man in his early 70s who received several different lines of therapy for non-muscle-invasive bladder cancer (NMIBC), wants to avoid radical cystectomy and does not want pembrolizumab (0:00)Case: A man in his late 70s with newly diagnosed NMIBC with carcinoma in situ (11:20)CME information and select publications
Fri, 14 Aug 2026 - 22min - 627 - Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Roles of CAR T-Cell Therapy and Bispecific Antibodies
Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Manali Kamdar, Dr Tycel Phillips and Dr Jason Westin, moderated by Dr Abramson, including the following topics:
Introduction (0:00)Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (2:16)Bispecific Antibody Therapy for DLBCL — Dr Westin (27:21)CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Abramson (51:10)Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:13:24)Tolerability Considerations with CAR T-Cell Therapy and Bispecific Antibodies — Dr Brody (1:37:47)CME information and select publications
Thu, 13 Aug 2026 - 1h 59min - 626 - Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Wassim Abida, Dr Rahul Aggarwal, Dr Emmanuel S Antonarakis, Prof Karim Fizazi and Dr Rana R McKay, moderated by Dr McKay, including the following topics:
Introduction (0:00)Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Antonarakis (2:42)Current and Future Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Aggarwal (26:23)Current and Future Role of Regimens Combining PARP Inhibitors and Androgen Receptor (AR) Pathway Inhibitors in Metastatic Prostate Cancer — Dr Abida (53:01)Emerging Role of AKT Inhibition for Patients with mHSPC — Prof Fizazi (1:17:22)Current and Future Use of Radiopharmaceuticals in Metastatic Prostate Cancer — Dr McKay (1:39:37)CME information and select publications
Wed, 12 Aug 2026 - 1h 59min - 625 - Myelofibrosis — Proceedings from a Webinar Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics:
Introduction (0:00)The Biopathophysiology of Myelofibrosis (MF) (2:19)Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49)Managing MF for Patients with Anemia and Thrombocytopenia — Dr Rampal (35:00)Upcoming at European Hematology Association (EHA) 2026 (49:22)CME information and select publications
Tue, 11 Aug 2026 - 57min - 624 - For Oncology Nurses: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics:
Introduction (00:00)Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45)Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00)Strategies to Prevent and Manage Hyperglycemia (27:02)Clinical Utility of Capivasertib for HR-Positive mBC (38:09)Mitigation and Management of Gastrointestinal Adverse Events (51:05)Management of Dermatologic Adverse Events (59:58)Potential Role of Gedatolisib in the Management of HR-Positive mBC (1:08:42)Monitoring and Management of Cytopenias (1:21:23)CME information and select publications
Mon, 10 Aug 2026 - 1h 29min - 623 - Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Anne Chiang, Dr Apar Kishor Ganti, Dr Luis Paz-Ares and Dr Misty Dawn Shields, moderated by Dr Shields, including the following topics:
Introduction (0:00)Optimizing First-Line and Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (SCLC) — Dr Shields (2:17)Management of Relapsed/Refractory SCLC — Dr Paz-Ares (33:24)Ongoing Investigation and Potential Role of Antibody-Drug Conjugates in SCLC — Dr Chiang (1:02:28)Management of Limited-Stage SCLC — Dr Ganti (1:31:54)CME information and select publications
Fri, 07 Aug 2026 - 1h 59min - 622 - Gastroesophageal Cancers — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Prof Eric Van Cutsem, moderated by Dr Janjigian, including the following topics:
Introduction (0:00)HER2-Targeted Approaches in Advanced Gastroesophageal Cancers — Prof Van Cutsem (2:08)Targeting CLDN18.2 in Advanced Gastroesophageal Cancers — Dr Shah (30:54)Available Immunotherapeutic Strategies for Advanced Gastroesophageal Cancers — Dr Janjigian (1:01:39)CME information and select publications
Thu, 06 Aug 2026 - 1h 28min - 621 - Chronic Lymphocytic Leukemia — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics:
Introduction (0:00)Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22)Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24)Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31)Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01)Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24)CME information and select publications
Wed, 05 Aug 2026 - 2h 00min - 620 - Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR
Featuring perspectives from Dr John V Heymach and Dr Maurice Pérol, including the following topics:
Introduction: Relative Impact of Targeted Treatment (00:00)HER2 Alterations (8:04)KRAS Mutations (24:25)MET Overexpression (30:34)ALK Fusions (32:34)ROS1 Fusions (42:36)RET Fusions (52:00)CME information and select publications
Mon, 03 Aug 2026 - 59min - 619 - For Oncology Nurses: Relapsed/Refractory Multiple Myeloma — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics:
Introduction (0:00)Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44)Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00)Utility of Belantamab Mafodotin in R/R MM (49:29)Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01)CME information and select publications
Mon, 03 Aug 2026 - 1h 26min - 618 - TROP2- and CDH6-Directed ADCs in Gynecologic Cancers — An Interview with Dr Ramez Eskander on Key Presentations from the Society of Gynecologic Oncology 2026 Annual Meeting
Featuring an interview with Dr Ramez Eskander, including the following topics:
Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00)Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53)Comparative efficacy and safety of ADCs and conventional chemotherapy (12:58)Current and investigational targets of ADCs in gynecologic cancers (17:14)Current research surrounding raludotatug deruxtecan (R-DXd) and its potential role in clinical practice (21:56)Safety and tolerability profiles of ADCs, including R-DXd, and potential mitigation strategies (27:36)Overview of available TROP2-directed ADCs for gynecologic cancers, including key clinical data (33:34)Evolving use of TROP2-directed ADCs for gynecologic cancers in clinical trials (39:05)Oral mucositis/stomatitis associated with TROP2-directed ADCs and potential mitigation strategies (44:38)CME information and select publications
Sat, 01 Aug 2026 - 54min - 617 - HER2-Altered Non-Small Cell Lung Cancer — 5-Minute Journal Club: Microlearning Activity 3
Featuring perspectives from Dr Joshua K Sabari, including the following topics:
Jänne PA et al. Final analysis results and patient-reported outcomes from DESTINY-Lung02 — A dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC. J Thorac Oncol 2025;20(12):1814-28. (0:00)Heymach JV et al. Circulating tumor DNA (ctDNA) analysis following zongertinib treatment (tx) in patients (pts) with human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC): Phase Ia/Ib Beamion LUNG-1 study. ESMO 2025;Abstract 2020P. (8:30)Schram AM et al. Beamion PANTUMOR-1: Rationale and design of a phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors. Future Oncol 2026;22(7):795-803. (12:53)Johnson ML et al. Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care in patients with locally advanced/metastatic non-squamous NSCLC harboring HER2 tyrosine kinase domain (TKD) mutations. ASCO 2024;Abstract TPS8654. (19:40)Le X et al. SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations. ASCO 2025;Abstract TPS8648. (21:41)Li BT et al. Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04). ASCO 2022;Abstract TPS9137. (22:59)Jänne PA et al. Trastuzumab deruxtecan for ERBB2-mutant metastatic NSCLC with or without brain metastases: A secondary analysis of randomized clinical trials. JAMA Netw Open 2025;8(11):e2543107. (24:37)CME information and select publications
Thu, 30 Jul 2026 - 30min - 616 - HER2-Altered Non-Small Cell Lung Cancer — 5-Minute Journal Club: Microlearning Activity 2
Featuring perspectives from Dr Joshua K Sabari, including the following topics:
Heymach JV et al. Zongertinib in previously treated HER2-mutant non-small cell lung cancer. N Engl J Med 2025;392(23):2321-33. (0:00)Popat S et al. Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG-1. ESMO 2025;Abstract LBA74. (5:25)Le X et al. Sevabertinib in advanced HER2-mutant non-small cell lung cancer. N Engl J Med 2025;393(18):1819-32. (12:37)CME information and select publications
Thu, 30 Jul 2026 - 16min - 615 - For Oncology Nurses: CDK4/6 Inhibitors for Breast Cancer — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following topics:
Introduction (00:00)Advent of CDK4/6 Inhibitors in HR-Positive Breast Cancer (BC) (1:24)Risk Assessment for Patients with HR-Positive, HER2-Negative Localized BC (2:52)Adjuvant CDK4/6 Inhibitor Therapy (17:14)Practical Considerations with CDK4/6 Inhibitors (29:57)Monitoring and Management of Cytopenias (42:02)CDK4/6 Inhibitors in HR-Positive Metastatic BC (49:32)Management of Gastrointestinal Adverse Events (1:03:47)CDK4/6 Inhibitors in Unique Populations (1:10:41)Rarer CDK4/6 Inhibitor-Associated Toxicities (1:19:48)CME information and select publications
Wed, 29 Jul 2026 - 1h 29min - 614 - Colorectal Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Stacey A Cohen and Dr Arvind Dasari, moderated by Dr Bekaii-Saab, including the following topics:
Introduction (0:00)Current and Future Role of Immune Checkpoint Inhibition in the Management of Microsatellite Instability-High/Mismatch Repair Deficient Localized and Locally Advanced Colorectal Cancer (CRC) — Dr Cohen (1:45)Clinical Relevance and Practical Utilization of Molecular Residual Disease Analysis in CRC — Dr Dasari (34:08)Recent Advances in Metastatic CRC: Optimizing Immunotherapy and Other Approaches — Dr Bekaii-Saab (1:00:42)CME information and select publications
Tue, 28 Jul 2026 - 1h 29min - 613 - Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 1
Featuring perspectives from Dr Mazyar Shadman, including the following topics:
The CLL17 trial: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL) (0:00)The AMPLIFY trial: Fixed-duration acalabrutinib combinations for untreated CLL (5:31)Zanubrutinib-based therapy for treatment-naïve CLL (12:32)CME information and select publications
Mon, 27 Jul 2026 - 22min - 612 - Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 2
Featuring perspectives from Dr Mazyar Shadman and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:
Case: A man in his mid 40s with chronic lymphocytic leukemia (CLL) receives acalabrutinib/venetoclax as part of the MAJIC trial (0:00)Case: A man in his early 70s with TP53-mutated CLL expresses concern about side effects associated with zanubrutinib (8:22)Case: A man in his late 70s with Stage IIIB chronic kidney disease and CLL receives obinutuzumab (18:02)CME information and select publications
Mon, 27 Jul 2026 - 29min - 611 - Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway
Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics:
Introduction(0:00)Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor Degraders (SERDs) in First-Line Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Turner (2:35)Role of Oral SERD Monotherapy in the Treatment of Progressive HR-Positive, HER2-Negative mBC — Dr O’Shaughnessy (25:23)Potential Use of Oral SERD-Containing Combination Regimens in Managing Progressive HR-Positive, HER2-Negative mBC — Dr Mayer (46:29)Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive, HER2-Negative mBC — Dr Hurvitz (1:07:06)Potential Use of Oral SERDs for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Tolaney (1:38:17)CME information and select publications
Sat, 25 Jul 2026 - 1h 58min - 610 - For Oncology Nurses: Ovarian Cancer — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Dr Bradley J Monk, Dr David M O’Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O’Malley, including the following topics:
Introduction(00:00)Overview of Ovarian Cancer (OC) (2:12)Role of PARP Inhibitors in Advanced OC (4:56)Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45)Role of Relacorilant in Advanced OC (57:08)Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12)NCPD information and select publications
Thu, 23 Jul 2026 - 1h 30min - 609 - Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Melissa Alsina, Dr Hans Lee, Dr Sagar Lonial and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics:
Introduction(0:00)Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lee (1:45)Current Utility of Antibody-Drug Conjugates for MM — Dr Lonial (33:55)Potential Role of Cereblon E3 Ligase Modulators in Therapy for MM — Dr Richardson (59:42)Chimeric Antigen Receptor T-Cell Therapy for R/R MM — Dr Alsina (1:30:24)CME information and select publications
Wed, 22 Jul 2026 - 1h 57min - 608 - EGFR-Mutated Non-Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Sarah B Goldberg, Dr Jonathan Goldman, Dr Joel W Neal, Dr Antonio Passaro and Dr Jacob Sands, moderated by Dr Sands, including the following topics:
Introduction(00:00)Evolving First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Prof Passaro (2:27)EGFR-Targeted Therapeutic Strategies for Relapsed EGFR-Mutant NSCLC — Dr Neal (36:08)Utility of TROP2-Targeted Antibody-Drug Conjugates in the Management of EGFR-Mutant NSCLC — Dr Sands (56:16)Emerging Role of Bispecific Antibody-Based Approaches for EGFR-Mutated NSCLC — Dr Goldman (1:19:08)Tolerability Considerations with the Use of Available and Emerging Therapies for EGFR-Mutated NSCLC — Dr Goldberg (1:38:46)CME information and select publications
Tue, 21 Jul 2026 - 1h 57min - 607 - Endometrial Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Floor J Backes, Dr Brian M Slomovitz and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:
Introduction(00:00)Current Up-Front Chemoimmunotherapeutic Approaches for Advanced Endometrial Cancer (EC) — Dr Backes (1:50)Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy for Advanced EC — Dr Westin (33:15)Promising Agents Under Investigation for EC — Dr Slomovitz (1:01:41)CME information and select publications
Mon, 20 Jul 2026 - 1h 29min - 606 - HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy
Featuring an interview with Prof Dr Sibylle Loibl, including the following topics:
Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00)Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35)Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01)Targeting the PI3K signaling pathway in HER2-positive mBC (11:08)Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung disease (13:53)Optimal duration of and therapeutic partner for T-DXd as first-line maintenance therapy for patients with HER2-positive mBC (20:44)Case: A woman in her early 40s with metastatic relapse of HER2-positive breast cancer 2 years after completing neoadjuvant and adjuvant therapy (26:54)Role of exercise and weight control in the management of breast cancer; effect of pregnancy on the breast tumor immune environment (40:03)CME information and select publications
Fri, 17 Jul 2026 - 46min - 605 - For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics:
Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00)Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49)Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48)Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43)Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43)Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15)Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30)CME information and select publications
Thu, 16 Jul 2026 - 1h 58min - 604 - Ovarian Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Ramez N Eskander, Dr Ursula Matulonis, Dr Kathleen N Moore, Dr Alexander B Olawaiye and Dr David M O'Malley, moderated by Dr Moore, including the following topics:
Introduction (00:00)Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC) — Prof Eskander (2:40)Strategies Targeting Folate Receptor Alpha in Advanced OC — Dr Matulonis (27:41)Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC — Dr Moore (52:12)Other Novel Agents and Strategies for Advanced OC — Dr O'Malley (1:14:35)Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC — Dr Olawaiye (1:39:39)CME information and select publications
Wed, 15 Jul 2026 - 2h 01min - 603 - HER2-Altered Non-Small Cell Lung Cancer — Rapid Case Review
Featuring an interview with Dr Mark Jeng and Dr Joshua K Sabari, including the following topics:
Case: A woman in her late 90s with recurrent HER2-mutant metastatic non-small cell lung cancer (NSCLC) receives third-line zongertinib (0:00)Case: A woman in her early 60s with multiregimen-recurrent HER2-mutant metastatic NSCLC experiences a response to zongertinib (8:07)Case: A man in his mid 80s experiences metastatic recurrence after resection of PD-L1-positive, HER2-mutant metastatic NSCLC (17:50)CME information and select publications
Tue, 14 Jul 2026 - 27min
Podcasts ähnlich wie Oncology Today with Dr Neil Love
El Partidazo de COPE COPE
Herrera en COPE COPE
La Linterna COPE
Es la Mañana de Federico esRadio
La noche de Cuesta esRadio
La Trinchera de Llamas esRadio
Hondelatte Raconte Europe 1
Affaires sensibles France Inter
LEGEND Guillaume Pley
CHRONIQUES CRIMINELLES Jacques Pradel - TF1
El colegio invisible OndaCero
La Rosa de los Vientos OndaCero
Les grands dossiers de l'Histoire par Franck Ferrand Radio Classique
Espacio en blanco Radio Nacional
Entrez dans l'Histoire RTL
Le grand récit RTL
Les Grosses Têtes RTL
L'Heure Du Crime RTL
El Larguero SER Podcast
Nadie Sabe Nada SER Podcast
SER Historia SER Podcast
Todo Concostrina SER Podcast
Un Libro Una Hora SER Podcast
HISTORIAS DE LA HISTORIA VIVA RADIO